Si-Bone ( (SIBN) ) has released its Q2 earnings. Here is a breakdown of the information Si-Bone presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SI-BONE, Inc. is a medical device company specializing in innovative solutions for sacropelvic disorders, leveraging minimally invasive surgical technologies. In its second-quarter 2025 earnings report, SI-BONE announced a significant revenue increase of 21.7% year-over-year, reaching $48.6 million, and achieved positive adjusted EBITDA and cash flow breakeven. Key financial highlights include a 22.8% growth in U.S. revenue and a gross margin improvement to 79.8%. The company also reported a net loss reduction of 31.2% to $6.2 million. Operationally, SI-BONE expanded its physician base by 25% and launched new products in Europe. Looking ahead, SI-BONE has raised its 2025 revenue guidance to $195-$198 million, projecting continued growth and profitability, while maintaining a strong focus on innovation and market expansion.